Population pharmacokinetics of raltitrexed in patients with advanced solid tumours

British Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2004, Pages 416-426

  Blair, Elaine Y L ^a   Rivory, Laurent P ^b,c,d   Clarke, Stephen J ^c   McLachlan, Andrew J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

Cancer; Population pharmacokinetics; Raltitrexed

Indexed keywords

CREATININE; RALTITREXED; SERUM ALBUMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARTMENT MODEL; CONCENTRATION RESPONSE; COVARIANCE; CREATININE CLEARANCE; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; GENETIC VARIABILITY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NONLINEAR SYSTEM; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VALIDATION PROCESS; VARIANCE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; THIOPHENES;

EID: 1942455391     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02050.x     Document Type: Article

References (40)

1. Cunningham D, Zalcberg JR, Rath U et al. Final results of a randomised trial comparing Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-5.
2. Cocconi C, Cunningham D, Van Cutsem E et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 2943-52.
3. Smith I, Jones A, Spielmann M et al. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 1996; 74: 479-81.
4. Jackman AL, Taylor GA, Gibson W et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51: 5579-86.
5. Jackman AL, Farrugia DC, Gibson W et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995; 31A: 1277-82.
6. Clarke SJ, Hanwell J, de Boer M et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996; 14: 1495-503.
7. Grem JL, Sorensen JM, Cullen E et al. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clin Cancer Res 1999; 5: 2381-91.
8. 14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 1998; 42: 71-6.
9. Judson I, Maughan T, Beale P et al. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br J Cancer 1998; 78: 1188-93.
10. Jodrell DI, Newell DR, Gibson W, Hughes LR, Calvert AH. The pharmacokinetics of the quinazoline antifolate ICID1694 in mice and rats. Cancer Chemother Pharmacol 1991; 28: 331-8.
11. Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 2000; 39: 429-43.
12. Clarke SJ, Farrugia DC, Aherne GW, Pritchard DM, Benstead J, Jackman AL. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity. Clin Cancer Res 2000; 6: 285-96.
13. Morrison PF, Allegra CJ. The kinetics of methotrexate polyglutamation in human breast cancer cells. Arch Biochem Biophys 1987; 254: 597-610.
14. Judson IR. Tomudex' (raltitrexed) development: preclinical, phase I and II studies. Anticancer Drugs 1997; 8: S5-S9.
15. Maughan TS, James RD, Kerr DJ et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555-63.
16. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56: 1019-38.
17. Kastrissios H, Ratain MJ. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. Cancer Invest 2001; 19: 57-64.
18. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209.
19. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-72.
20. Toffoli G, Corona G, Sorio R et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 2001; 52: 511-19.
21. Mould DR, Holford NHG, Schellens JHM et al. Population pharmacokinetics and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002; 71: 334-48.
22. Aherne GW, Ward E, Lawrence N et al. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models. Br J Cancer 1998; 77: 221-6.
23. Nath CE, McLachlan AJ, Shaw PJ, Gunning R, Earl JW. Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol 2001; 52: 671-80.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
25. FDA. FDA Guidelines. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: US Food and Drug Administration, 1999.
26. Roecker EB. Prediction error and its estimation for subset-selected models. Technometrics 1991; 33: 459-68.
27. Bressolle F, Bologna C, Edno L et al. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol 1996; 49: 285-92.
28. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377-84.
29. de Alwis DP, Aarons L, Palmer JL. Population pharmacokinetics of ondansetron: a covariate analysis. Br J Clin Pharmacol 1998; 46: 117-25.
30. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994; 22: 431-45.
31. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995; 12: 1845-55.
32. InnaPhase. P-Pharm methodology. In P-Pharm, Version 1.5.1. User's Manual. Champs-sur-Marne, France: InnaPhase, 1998.
33. Gomeni R, Pineau G, Mentre F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res 1994; 14: 2321-6.
34. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
35. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998; 34: 33-46.
36. Clarke SJ. The Toxicities of the novel thymidylate synthase inhibitor ICID1694, in mouse and man [Thesis]. London: London University, 1994.
37. van den Bongard HJ, Mathot RA, Beijnen JH, Schellens JH. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345-67.
38. Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94: 1883-8.
39. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-50.
40. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16: 253-62.